car-t, bispecifics and mrd: how is treatment for multiple myeloma evolving?
Published 2 years ago • 124 plays • Length 0:39Download video MP4
Download video MP3
Similar videos
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
1:31
integrating bcma-directed bispecifics and car-t into the myeloma treatment landscape
-
1:42
how to best sequence bispecific antibodies and car-t therapy in multiple myeloma
-
3:06
management of multiple myeloma during car-t therapy manufacturing
-
2:29
the safety and feasibility of car-t & bispecifics in patients with myeloma after prior allosct
-
4:36
q&a | how to sequence car t-cell therapy and bispecific antibodies in r/r mm
-
7:14
car-ts in multiple myeloma: their current role and the future
-
47:11
asco/eha 2023 special: updates on car t-cell therapy in myeloma
-
2:10
mechanisms of resistance to car t-cells in myeloma & future considerations
-
1:53
car-t therapy in multiple myeloma: research blind spots
-
1:45
the role of non-covalent btkis in the era of covalent btkis for b-cell malignancies
-
4:58
novel immunotherapies transforming r/r myeloma treatment: bispecifics, car-t cells & more
-
2:19
novel avenues for mm treatment: car t-cells, venetoclax, induction & mrd
-
1:53
phe885, a t-charge manufactured bcma-directed car-t therapy in r/r myeloma
-
5:46
where in the treatment sequence should car t-cells be used for myeloma?
-
1:15
how bcma targeting bispecific antibodies may impact the subsequent use of car-t therapy in myeloma
-
6:40
car-t vs bispecifics: the best immune approach to replace asct
-
2:10
session highlights: clinical indications for car-t therapy in multiple myeloma
-
4:35
bispecific antibodies vs car t-cells for r/r multiple myeloma
-
2:16
the sequencing of novel therapies in myeloma (car-t, bispecifics, antibody-drug conjugates)
-
1:21
developing off-the-shelf car t-cells to treat multiple myeloma
-
2:01
bite and car-t combinations for myeloma